tbuckley/cabot-search huggingface dataset:
A review of wearable technology in medicine
Authors: Mohammed H Iqbal, Abdullatif Aydin, Oliver Brunckhorst, Prokar Dasgupta, Kamran Ahmed
Journal: Journal of the Royal Society of Medicine (2016)

With rapid advances in technology, wearable devices have evolved and been adopted for various uses, ranging from simple devices used in aiding fitness to more complex devices used in assisting surgery. Wearable technology is broadly divided into head-mounted displays and body sensors. A broad search of the current literature revealed a total of 13 different body sensors and 11 head-mounted display devices. The latter have been reported for use in surgery ( n = 7), imaging ( n = 3), simulation and education ( n = 2) and as navigation tools ( n = 1). Body sensors have been used as vital signs monitors ( n = 9) and for posture-related devices for posture and fitness ( n = 4). Body sensors were found to have excellent functionality in aiding patient posture and rehabilitation while head-mounted displays can provide information to surgeons to while maintaining sterility during operative procedures. There is a potential role for head-mounted wearable technology and body sensors in medicine and patient care. However, there is little scientific evidence available proving that the application of such technologies improves patient satisfaction or care. Further studies need to be conducted prior to a clear conclusion.
Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease
Authors: M-T Rubio, M Bouillié, N Bouazza, T Coman, H Trebeden-Nègre, A Gomez, F Suarez, D Sibon, A Brignier, E Paubelle, S Nguyen-Khoc, M Cavazzana, O Lantz, M Mohty, S Urien, O Hermine
Journal: Leukemia (2016)
Quantitative Analysis of the Domain-Specific Autoantibodies to ADAMTS13 in Patients with Acquired Thrombotic Thrombocytopenic Purpura
Authors: Atsuko Igari, Takanori Moriki, Yusuke Yamaguchi, Terumichi Nakagawa, Hideo Wada, Masanori Matsumoto, Yoshihiro Fujimura, Kenji Soejima, Mitsuru Murata
Journal: Blood (2011)
TCT-244 The Impella to Balloon (ITB) Strategy Limits Infarct Size and Improves Survival in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Bench to Bedside Study
Authors: Navin K. Kapur, Vikram Paruchuri, Xiaoying Qiao, Kevin Morine, Lyanne Buiten, Noam Josephy, Emily E. Mackey, William W. O'Neill, Richard H. Karas
Journal: Journal of the American College of Cardiology (2015)
Monitoring of CD8+ T cell-specific response to ErbB-2 and hMena in advanced NSCLC patients (pts)
Authors: P. Nistico, M. Milella, D. Del Bello, A. Ranieri, B. Di Cocco, M. Mottolese, A. Di Benedetto, F. Di Modugno, F. Cognetti, A. Ceribelli
Journal: Journal of Clinical Oncology (2004)

9674 Background: increasing evidence indicates that tumor pts are able to spontaneously generate specific humoral and cellular antitumor immune responses. In NSCLC antibody and cytotoxic T lymphocyte (CTL) responses have been described against different targets, including ErbB-2. We have recently demonstrated that hMena, a SEREX-defined antigen overexpressed in different tumor tissues, is able to induce a cancer-restricted humoral response in different tumor pts. In particular, we have demonstrated a coordinated antibody and CTL immune response to three different hMena epitopes in HLA-A2+ breast cancer pts. In this study, we have analyzed ex-vivo CD8+ T cell responses specific for ErbB-2 and hMena peptides in advanced NSCLC pts. Methods: blood samples from 54 advanced NSCLC pts were consecutively collected and separated to obtain PBL and serum. HLA-A2 phenotype was assessed by cytofluorimetric analysis with B.B72 mAb. CD8+ T cells were isolated from PBL using immunomagnetic beads and tested for IFN-g production against HLA-A2 binding peptides using a computer-assisted ELISPOT assay. Results: HLA-A2 phenotyping revealed that 24 out of 54 (44%) pts were HLA-A2+. Preliminary evaluation by ex vivo ELISPOT in 12 HLA-A2+ NSCLC pts demonstrated a CTL response against different ErbB-2 (p48, p369, p435, p689, p789) and hMena (hMena-443, hMena-502, hMena-562) peptides in all but three pts. The pattern of CTL response against different peptides varied from patient to patient and was preferentially directed against epitopes that do not appear to be dominant in breast cancer. CTL response was detectable at diagnosis, before any chemotherapy was started, and persisted, though with variations in the pattern of peptide specificity, during and after treatment, which consisted of gemcitabine/platinum combinations ± COX-2 inhibitors in all but one pt. The correlation between CTL response, antigen overexepression in tumor lesions, and clinical course is currently being evaluated. Conclusions: CTL responses against erbB-2 and hMena are detectable in NSCLC and may have implications in the development of novel, combined therapeutic strategies. No significant financial relationships to disclose.
TCT-163 Physiologic Assessment of Intermediate Coronary Artery Stenosis by Intravascular Ultrasound Radiofrequency Signal Analysis of Blood Speckles: A Comparison with Fractional Flow Reserve and Instantaneous Wave-Free Ratio
Authors: Kozo Okada, Kiyoshi Hibi, Kensuke Matsushita, Hideki Kitahara, Peter J. Fitzgerald, Satoshi Umemura, Yasuhiro Honda, Kazuo Kimura
Journal: Journal of the American College of Cardiology (2015)
Abstracts from the Twelfth International Symposium on Pediatric Neuro-Oncology
Authors: S Laughton, T Merchant, A Broniscer, M Fouladi, L Kun, A Gajjar, T Tamura, I Tsumanuma, K Nishiyama, J Yoshimura, R Tanaka, D Mabbott, M Noseworthy, S Laughlin, C Rockel, E Bouffet, D Bowers, D Mcneil, Y Liu, W Leisenring, M Stovall, J Gurney, L Robison, R Packer, K Oeffinger, E Morris, J Okuma, D Wallace, M Hudson, K Sugiyama, K Arita, K Kurisu, S Sands, I Dunkel, S Gardner, J Allen, A Termuhlen
Journal: Neuro-Oncology (2007)

Purpose: To estimate the frequency and severity of endocrine effects in a cohort of children with embryonal tumors treated with craniospinal and conformal primary site irradiation using clinical variables and hypothalamus-pituitary axis (HPA) dosimetry.Methods: Clinical data were obtained from patient records and institutional databases for children treated at St. Jude Children's Research Hospital on the SJMB96 protocol.Analysis was restricted to those 77 of 82 children with medulloblastoma, who survived at least two years from diagnosis.The craniospinal irradiation dose was 23.4 Gy for average-risk (AR) and 36.0-39.6Gy for high-risk (HR) children.The posterior fossa compartment was boosted to 36 Gy in AR, and the primary site, for both risk categories, to 55.8-59.4Gy.Results: Radiation doses to the hypothalamus and pituitary were 38.7 Gy (range, 26.3-50.1)and 41.2 Gy (range, 28.8-54.8) in the 47 AR children, and 48.1 Gy (range, 39.3-56.2) and 50.1 Gy (range, 38.4-56.6) in the 30 HR children.Thyroxine (LT4) replacement therapy was commenced in 62 children at a median of 1.95 years (range, 0.90-4.62),hydrocortisone (HC) in 27 children at a median of 1.99 years (range, 0.86-5.65),and growth hormone (GH) in 44 children at a median of 2.23 years (range, 1.40-4.36)after irradiation.The mean hypothalamic radiation dose was higher in children who subsequently required LT4 replacement (42.6 Gy compared to 38.7 Gy, P 5 0.04), as was the pituitary dose (45.6 Gy compared to 39.9 Gy, P 5 0.003).No association between hypothalamic or pituitary radiation dose and HC or GH requirement was seen.Mean height Z scores fell from 0.21 at diagnosis to -0.47, -0.93, and -1.01 at one, two, and three years after radiation, respectively.Height Z scores at three years were lower in those who received a higher hypothalamic dose (-1.25 compared to -0.83, P 5 0.052).Summary: There was a statistically significant relationship between radiation dose to the HPA and the incidence of hypothyroidism requiring replacement therapy.Although other endocrine deficits are common after treatment, they appear to be multifactorial in their etiology.Minimizing dose to the HPA is an important treatment objective, and further investigation is warranted to determine the incidence, time course, and influence of clinical and dosimetric factors.
GW27-e0552 Novel single nucleotide polymorphisms identified in Exon-10 of Human coagulation factor V gene in patients with pulmonary embolism.
Authors: Rajasekhar Durgaprasad, Vamsidhar Akkulagari, Latheef Kasala, Vanajakshamma Velam, Sarma PVGK
Journal: Journal of the American College of Cardiology (2016)
Towards Personalized Therapy in Pediatric Acute Lymphoblastic Leukemia; Ras Mutations and Prednisolone Resistance
Authors: Ingrid M. Ariës, Rosanna van den Dungen, Marco Koudijs, Edwin Cuppen, Emile E. Voest, Jan J Molenaar, Huib N. Caron, Rob Pieters, Monique L. Den Boer
Journal: Blood (2014)
Effects of aerobic exercise training on physical performance during myeloablative therapy
Authors: M. de Wit, Z. Seyfi, Y. Süsse, K. Oechsle, C. Bokemeyer
Journal: Journal of Clinical Oncology (2008)

9502 Background: Cancer disease and treatment-related effects during long or recurrent hospitalization induce loss of physical performance of patients. The aim of this study were to evaluate the effects of aerobic exercise training on physical performance in patients with haematological malignancies or solid tumours during myeloablative antileucemic therapy or high dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Methods: In this prospective controlled study fifthy-eight patients with were randomly assigned to a training (TG, n= 29) or control (CG, n=29) group. The TG performed an individual supervised exercise program with ergometer training for 10 min and three exercises using the main muscle groups for 20 min, five times per week during hospitalization.Patients in the CG did not train, but they received physiotherapy as usually indicated. At the beginning and the end of each cycle of chemotherapy physical performance was evaluated with spiroergometry including lactate controls, immune system function with flow cytometry and blood samples.Treatment related side effects were documented by daily patients-interviews and quality of life by EORTC-QLQ-30 questionnaire. Results: There was a significant increase in physical performance of the TG 8,96±24 W and a decrease in the CG -7,24±20 W, p=0,02, thus the study met the primary endpoint. At 2mmol/ml blood lactate concentration the TG achieved significant increased oxygen consumption VO2 (p=0,03) and minute ventilation VE (p=0,04) compared to the CG. Furthermore the TG achieved an increase in physical functioning score (p=0,04) and complained significantly less days of fatigue compared to the CG (p=0,05). The TG also consumed less antiemetics (p=0,01). The other varibles showed no significant changes between both groups. Conclusions: These results demonstrate positive effects of aerobic exercise on the physical performance and treatment-related symptoms during myeloablative chemotherapy. We suggest an enhanced physical activity intervention during hospitalization of cancer patients. No significant financial relationships to disclose.
TCT-340 Impact of Side Branches Modeling on Computation of Endothelial Shear Stress in Coronary Artery Disease: a Novel Method for Patient-Specific Coronary Tree Reconstruction by Fusion of X-ray Angiography and Optical Coherence Tomography
Authors: Yingguang Li, Juan Luis Gutiérrez-Chico, Niels R. Holm, Wenjie Yang, Lasse Hebsgaard, Evald H. Christiansen, Michael Maeng, Jens Flensted F. Lassen, Fuhua Yan, Johan H. Reiber, Shengxian Tu
Journal: Journal of the American College of Cardiology (2015)
Incidence of brain metastases in HER-2 positive (early and metastatic) breast cancer patients treated with trastuzumab—The Sultanate of Oman experience 2002–2007
Authors: A. Khalifa, M. Faris
Journal: Journal of Clinical Oncology (2008)

14674 Background: The incidence of HER-2 over expression among Omani breast cancer patients was reported as 40% (higher than international published figures). Since 2002 a total of 76 patients with early and metastatic breast cancer received Trastuzumab, the results and incidence of developing brain metastasis during treatment are presented. Methods: Prospective, single arm, single centre experience. Patients with confirmed HER-2 positive (+++ by Herceptest, or FISH positive) breast cancer who received Trastuzumab (either as adjuvant or for metastatic disease) were included. Eligible patients were aged > 18, ECOG PS ≤ 2, LVEF >50% and with adequate renal & liver function and with no evidence of brain metastasis prior to starting treatment. Adjuvant Trastuzumab was received for 1 year following chemotherapy in early breast cancer cases or as a single agent or in combination with chemotherapy as indicated in metastatic cases. A loading dose of 8mg/kg was followed by 6mg/kg q3 weeks. Results: a total of 76 patients were included between October 2002-October 2007, median age was 47years (23–69), 48 patients presented with either metastasis at first presentation or 6 months or more after finishing adjuvant chemotherapy, and the remaining 28 patients received adjuvant trastuzumab. Sixteen patients developed brain metastasis while on trastuzumab, 14 patients out of the 48 metastatic patients (29%) developed brain metastasis while on treatment and were showing response in the extra cranial systemic metastasis at the same time. Two out of the 28 patients who were receiving adjuvant Trastuzumab developed brain metastasis during treatment and received whole brain irradiation with disease control. (7%). The median time to developing brain metastasis in metastatic cases was 9m (range 4–33m), the 2 cases who progressed while receiving adjuvant Trastuzumab developed brain metastasis at 5months & 13months (mean 9m). There were 16 events (disease related deaths) during the study period and the median survival for the whole group was 15 months (range 4–36m). Conclusions: The incidence of developing brain metastasis during trastuzumab treatment in Omani patients is comparable to similar international studies. No significant financial relationships to disclose.
131I and 124I Accumulation in a Thymic Cyst
Authors: Tom Wilhelm, Thomas Winkens, Almut Kunze, Martin Freesmeyer
Journal: Clinical Nuclear Medicine (2016)

A 65-year-old woman presented with increased human thyroglobulin (3.3 ng/mL) 5 years after resection of a papillary thyroid carcinoma and successful I radioiodine therapy. I whole-body scintigraphy showed a small focus ventrally in the right lower neck, leading to suspicion of a papillary thyroid carcinoma recurrence. I-PET/CT and real-time PET/US fusion matched to a small hypoechoic/anechoic ovoid structure situated between the right sternoclavicular joint and the brachiocephalic trunk. After surgical resection, histology allowed a diagnosis of thymic cyst. A follow-up I whole-body scintigraphy showed no residual iodine accumulation.
Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.
Authors: Kurt Alex Schalper, Daniel E. Carvajal-Hausdorf, Joseph Francis McLaughlin, Mehmet Altan, Konstantinos N. Syrigos, Roy S. Herbst, David L. Rimm
Journal: Journal of Clinical Oncology (2015)

3067 Background: Expression of immune inhibitory signals such as co-regulatory ligands/receptors and tolerogenic enzymes by cancer cells limits the effectiveness of the immune surveillance. Blockade of such signals (e.g. CTLA-4 and PD-1/PD-L1) can reinvigorate the anti-tumor immune response and induce clinical benefit in a proportion of patients with advanced cancer. Methods: Using multiplexed quantitative immunofluorescence, we measured the levels of CD3 (E272-Novus), CD8 (C8/144B-DAKO), PD-L1 (E1L3N-CST), IDO-1 (1F8.2-Millipore) and B7-H4 (D1M8I-CST) in 554 stages I-IV lung carcinomas represented in two tissue microarrays, one from Yale U. (TM79 n = 204) and one from Greece (TM140 n = 350). The markers were measured in different tumor compartments based on their colocalization with pancytokeratin and DAPI. Associations between the marker levels, clinico-pathological variables and survival were determined. Results: PD-L1 was detected in 16.9% of cases in the Yale set and 20% of cases in the Greek collection. IDO-1 was expressed in 42.6% and 49.8%; and B7-H4 in 12.8% and 22.6% of cases, respectively. The levels of PD-L1 and IDO-1 were not consistently associated with sex, age and tumor histology. B7-H4 expression was significantly associated with squamous tumors in both collections (P = 0.041 and P < 0.0001, respectively). Elevated PD-L1 or IDO-1 was consistently associated with prominent CD3 and CD8+ T cells (P < 0.05), but B7-H4 was not. In univariable analysis, IDO-1 expression was significantly associated with longer overall survival in the Yale set (HR = 0.572 [CI:0.368-0.871], P = 0.009), but not in the Greek (HR = 0.883 [CI:0.636-1.220], P = 0.452). Expression of PD-L1 and B7-H4 were not significantly associated with survival. Tumors with prominent levels of one of the markers had typically low levels of the others, suggesting predominance of only one immune inhibitory pathway. Conclusions: PD-L1, IDO-1 and B7-H4 are differentially expressed in human lung carcinomas and have limited prognostic value. While the expression of PD-L1 and IDO-1 are associated with increased T-cells, B7-H4 is not. The high frequency of IDO-1 expression in lung tumors (~45%) suggests its potential for therapy, perhaps in combination with checkpoint inhibitors.
TCT-749 The Impact of Race and Gender on Procedural Outcomes After Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy
Authors: Stewart M. Benton, Jeremy D. Rier, Alexandria Panuccio, Shawn Shaji, Barbara E. Griffin, John M. Neathawk, Sheldon E. Litwin, Christopher D. Nielsen, Valerian Fernandes
Journal: Journal of the American College of Cardiology (2015)
TCT-674 Outcomes of Transfemoral Transcatheter Aortic Valve Implantation Utilizing a Minimally Invasive Strategy
Authors: Ahmad Alkhalil, Guilherme F. Attizzani, Bimal Padaliya, Chor Cheung Tam, Hiram Bezerra, Basar Sareyyupoglu, Alan Markowitz, Daniel Simon, Marco Costa
Journal: Journal of the American College of Cardiology (2015)
Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance
Authors: Robin P. Choudhury, Jacqueline S. Birks, Venkatesh Mani, Luca Biasiolli, Matthew D. Robson, Philippe L. L'Allier, Marc-Alexandre Gingras, Nadia Alie, Mary Ann McLaughlin, Craig T. Basson, Alison D. Schecter, Eric C. Svensson, Yiming Zhang, Denise Yates, Jean-Claude Tardif, Zahi A. Fayad
Journal: Journal of the American College of Cardiology (2016)

Evidence suggests that interleukin (IL)-1β is important in the pathogenesis of atherosclerosis and its complications and that inhibiting IL-1β may favorably affect vascular disease progression.The goal of this study was to evaluate the effects of IL-1β inhibition with canakinumab versus placebo on arterial structure and function, determined by magnetic resonance imaging.Patients (N = 189) with atherosclerotic disease and either type 2 diabetes mellitus or impaired glucose tolerance were randomized to receive placebo (n = 94) or canakinumab 150 mg monthly (n = 95) for 12 months. They underwent magnetic resonance imaging of the carotid arteries and aorta.There were no statistically significant differences between canakinumab compared with placebo in the primary efficacy and safety endpoints. There was no statistically significant change in mean carotid wall area and no effect on aortic distensibility, measured at 3 separate anatomic sites. The change in mean carotid artery wall area was -3.37 mm2 after 12 months with canakinumab versus placebo. High-sensitivity C-reactive protein was significantly reduced by canakinumab compared with placebo at 3 months (geometric mean ratio [GMR]: 0.568; 95% confidence interval [CI]: 0.436 to 0.740; p < 0.0001) and 12 months (GMR: 0.56; 95% CI: 0.414 to 0.758; p = 0.0002). Lipoprotein(a) levels were reduced by canakinumab compared with placebo (-4.30 mg/dl [range: -8.5 to -0.55 mg/dl]; p = 0.025] at 12 months), but triglyceride levels increased (GMR: 1.20; 95% CI: 1.046 to 1.380; p = 0.01). In these patients with type 2 diabetes mellitus or impaired glucose tolerance, canakinumab had no effect compared with placebo on any of the measures assessed by using a standard oral glucose tolerance test.There were no statistically significant effects of canakinumab on measures of vascular structure or function. Canakinumab reduced markers of inflammation (high-sensitivity C-reactive protein and interleukin-6), and there were modest increases in levels of total cholesterol and triglycerides. (Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients; NCT00995930).
Targeting the IL-2/CD25 and TL1A/TNFRSF25 Pathways: A New Approach to Markedly Expand Donor Tregs in Multiple Compartments Leads to in Situ Immune Regulation
Authors: Dietlinde Wolf, Henry Barreras, Cameron S Bader, Casey O Lightbourn, Brent J Pfeiffer, Eckhard R Podack, Krishna V Komanduri, Robert B. Levy
Journal: Blood (2015)
Reduction in breast cancer deaths is due to treatment not screening, finds study
Authors: Susan Mayor
Journal: BMJ (2016)

The fall in breast cancer mortality seen after widespread mammography screening was introduced in the US was mainly due to improved systemic therapy and not earlier detection of tumours, a comparison of national cancer data before and after the introduction of screening programmes has shown.

Researchers analysed data from the Surveillance, Epidemiology, and End Results population based cancer registry programme from 1975 to 2012 to calculate the distribution of tumour size and size specific incidence of breast cancer in …
Functional and Phenotypic Characterizations of Granulocyte-Colony Stimulating Factors Mobilzed CD34+ Cells.
Authors: Fontanet Bijou, Muhamed Hammoud, Marija Vlaski, Pascale Duchez, Noel-Jean Milpied, Xavier Lafarge, Jean Chevaleyre, Bouzgarrou Ridha, Bernard Dazey, Jean-Michel Boiron, Zoran Ivanovic
Journal: Blood (2009)
Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma
Authors: Jing Du, Martin Neuenschwander, Yong Yu, J. Henry M. Däbritz, Nina-Rosa Neuendorff, Kolja Schleich, Aitomi Bittner, Maja Milanovic, Gregor Beuster, Silke Radetzki, Edgar Specker, Maurice Reimann, Frank Rosenbauer, Stephan Mathas, Philipp Lohneis, Michael Hummel, Bernd Dörken, Jens Peter von Kries, Soyoung Lee, Clemens A. Schmitt
Journal: Blood (2016)